ArticleFrontiers in oncology2025
Securinine, a novel alkaloid, regulates cell cycle and EMT in gastric cancer by inducing iron-dependent cell death.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging role of plant-based compounds as ferroptosis modulators in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer remains one of the most prevalent and lethal cancers worldwide, with its insidious onset hindering early diagnosis and effective treatment. Despite advances, the overall survival rate for gastric cancer remains low, primarily due to late diagnosis, tumor heterogeneity, and resistance to current therapies. This highlights the urgent need for novel therapeutic strategies. Methods: Gastric cancer cell lines were treated with securinine, followed by analysis of cell proliferation, cycle, and Epithelial-Mesenchymal Transition (EMT) using Western blot and immunofluorescence techniques. Transcriptomic analysis was performed to identify changes in ferroptosis-related iron metabolism pathways. Results: Securinine significantly inhibited proliferation and modulated the cell cycle, arresting cells at the G2/M transition, while also enhancing EMT, which altered cell migration and invasiveness. Transcriptomic analysis revealed that securinine activated ferroptosis-related iron metabolic pathways, upregulating key genes such as HMOX1, FTH1, and FTR. Inhibition of these genes reversed the effects on cell proliferation and EMT, highlighting the role of ferroptosis in the anticancer effects of securinine. Conclusions: Securinine shows potential as a novel therapeutic agent for gastric cancer by inducing ferroptosis and modulating key cell death and survival pathways. Its ability to regulate iron metabolism and EMT suggests that it could be a promising candidate for developing new therapeutic strategies against gastric cancer, especially for drug-resistant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.